Quantcast
Last updated on April 16, 2014 at 12:31 EDT

Latest Tenaxis Medical Inc. Stories

2013-09-06 16:22:44

MOUNTAIN VIEW, Calif., Sept. 6, 2013 /PRNewswire/ -- Tenaxis Medical, Inc., (www.tenaxismedical.com), a medical device company focused on the development of functionally designed surgical sealants has received approval from its EU Notified Body, BSI, to expand its CE Mark indications for ArterX Surgical Sealant. ArterX Surgical Sealant is designed to be applied directly over suture or staple line to achieve hemostasis during surgery to seal the area to stop and prevent leaks. The...

2013-03-04 20:22:45

MOUNTAIN VIEW, Calif., March 4, 2013 /PRNewswire/ -- Tenaxis Medical, Inc., (www.tenaxismedical.com), a medical device company focused on the development of functionally designed surgical sealants has received FDA approval to bring its innovative ArterX Surgical Sealant to the market. The company plans to start commercialization of ArterX in the United States early in 2013. ArterX is the first product developed by Tenaxis and is specifically designed for use in vasculature reconstruction in...

2012-11-29 20:22:15

MOUNTAIN VIEW, Calif., Nov. 29, 2012 /PRNewswire/ -- Tenaxis Medical, Inc. (www.tenaxismedical.com) a medical device company focused on the development of functionally designed surgical sealants announced today that Dr. William E. Cohn has been added to its board of directors. Dr. Cohn is a cardiovascular surgeon and the Director of Minimally Invasive Surgical Technology at the Texas Heart Institute in Houston, Texas. In addition, he is co-director of the Cullen Cardiovascular Research...

2010-11-18 15:53:00

MOUNTAIN VIEW, Calif., Nov. 18, 2010 /PRNewswire/ -- US clinical trial results for Tenaxis' investigational vascular surgical sealant, ArterX, were presented today at the Veith Meeting in New York. William M. Stone, MD of the Mayo Clinic, Scottsdale AZ reported a more than 20% margin of improvement for ArterX Surgical Sealant in the sealing of vascular suture lines compared with a control group featuring a commercially available gelatin foam/thrombin combination. In a presentation...

2010-10-25 18:13:00

MOUNTAIN VIEW, Calif., Oct. 25 /PRNewswire/ -- Tenaxis Medical submitted its PMA to the FDA on July 27, 2010 and has now received confirmation from the FDA that "we have made a threshold determination that the PMA is sufficiently complete to permit a substantive review and is, therefore, suitable for filing." In the pivotal study designed to demonstrate superiority, the ArterX Surgical Sealant was compared to a thrombin soaked gelatin-sponge hemostat to reduce or eliminate suture line...

2010-03-04 15:12:00

MOUNTAIN VIEW, Calif., March 4 /PRNewswire/ -- The German Federal Patent Court in Munich has indicated their intention to nullify the German patent DE 693 31 011 (German Kowanko patent) assigned to CryoLife, Inc. of Kennesaw, GA. This is the German part of the European Patent 0 650 512 and is key intellectual property relating to the BioGlue® Surgical Adhesive which is marketed worldwide by CryoLife, Inc. "We have always believed our intellectual property protection to...

2010-01-25 16:54:00

MOUNTAIN VIEW, Calif., Jan. 25 /PRNewswire/ -- Tenaxis Medical has completed enrollment of its pivotal US study for the ArterX Vascular Sealant(TM). The study was designed to enroll up to 220 patients who were scheduled to receive a synthetic vascular graft or patch at 12 investigational sites within the US. Typical applications involved the placement of arteriovenous dialysis access grafts, carotid endarterectomy patches and large vessel reconstruction such as the open repair of...